British pharma giant GSK reports a Q3 loss due to Zantac cancer lawsuits—but CEO Emma Walmsley remains optimistic on delivering 2024 guidance

GSK suffered a loss after tax of £58 million ($75 million) in the July-September period compared with net profit of £1.5 billion one year earlier. Read More